Aclaris's drug to treat common growth on skin gets FDA nod [Reuters]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Reuters
Aclaris's drug to treat common growth on skin gets FDA nod | Reuters Reuters Staff 1 Min Read Dec 15 (Reuters) - Aclaris Therapeutics Inc said on Friday the U.S. Food and Drug Administration (FDA) had approved its topical drug to treat seborrheic keratoses, growths on the skin that are harmless but affect millions of Americans. Aclaris’s drug, Eskata, would be the first FDA-approved non-invasive treatment for the condition, the company said. Seborrheic keratoses are non-cancerous skin growths that affect more than 83 million adults in the United States, according to Aclaris. (Reporting by Divya Grover in Bengaluru; editing by Sai Sachin Ravikumar) All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2017 Reuters. All Rights Reserved. Aclaris's drug to treat common growth on skin gets FDA nod Dec 15 (Reuters) - Aclaris Therapeutics Inc said on Friday the U.S. Food and Drug Administration (FDA) had approved its topical drug to tre
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51% [Yahoo! Finance]Yahoo! Finance
ACRS
Earnings
- 2/27/24 - Beat
ACRS
Sec Filings
- 3/19/24 - Form 8-K
- 3/5/24 - Form 4
- 3/5/24 - Form 4
- ACRS's page on the SEC website